Navigation Links
A New BioPharma Intelligence Resource Set to Give Industry Leaders the Edge

A New BioPharma Intelligence Resource Set to Give Industry Leaders the Edge -- OXFORD, England, October 21, 2010 /PRNewswire/ --

Advanced Search Search

  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Multimedia & Internet, Publishing & Information Services, Biotechnology, Health Care & Hospitals, Medical Pharmaceuticals, New Products & Services Click to view news release full screen  

A New BioPharma Intelligence Resource Set to Give Industry Leaders the Edge


OXFORD, England, October 21, 2010 /PRNewswire/ -- In the current BioPharma economic climate; with smaller companies desperately needing the right development partners for survival and larger ones needing to support their existing businesses through making the right deals, having the best, most comprehensive, intelligence and insights are absolutely essential for success.

It is into this environment that PharmaTelevision Ltd (a subsidiary of PharmaVentures Ltd), announced today the launch of PharmaDeals(R) v4, the world's first online, multimedia, dedicated pharmaceutical industry deals intelligence resource.

Fintan Walton, PhD, Chief Executive of PharmaVentures says, "There are huge changes taking place in the world of deal making. There are more urgent needs for successful deals to be made and yet the resources required are harder to access. More companies are doing specialist deals, for example, with orphan drugs, and the world is changing as new technologies, mechanisms of action, and even new therapy areas, emerge."

"As leading practitioners of BioPharma deal making, we have worked diligently to develop an intelligence and insight resource that is truly at the cutting edge in terms of its delivery to customers, while we stay very focussed on ensuring quality of the content." Dr Walton continues, "PharmaDeals v4 gives executives within the biopharmaceutical and related industries, an ability to expand their understanding, deduce trends and extract vital intelligence needed for critical decision making, forming a significant part of the solution to help companies navigate these challenging times."

Steve MacKenzie-Lawrie (Director of Sales at PharmaTelevision) explains, "We took the existing PharmaDeals database and have made some truly significant developments. We have provided deeper classifications within drug delivery technologies and orphan drugs and following customer requests, the scope of the PharmaDeals v4 database has been expanded to now include categories of deals that have medical and therapeutic applications in cosmetics, nutritional supplements, packaging, wound care and bioterrorism".

MacKenzie-Lawrie expands, "Business intelligence and BD subscribers asked us to include share-price information, so we now have real-time links to stock markets, including NASDAQ & LSE, providing valuable information on the impact deals have made to the Company's share price."

Also, for the first time, the database now includes exclusive video interviews with deal makers around the world, allowing users to watch the major players in action and so deriving information simply not available elsewhere. This is invaluable in helping to understand and gain further insight into the individuals and companies involved in deal making, after all deal making is a people business.

Dr Walton concludes, "Gaining insight into the companies' deal making activities and the people behind the deals will help our subscribers when they come to negotiate with these individuals across the deal table. Watching the PharmaTelevision interviews is an informative way of doing their due diligence on the companies they want to partner with before they enter into negotiations. This is the icing on the cake."

About PharmaTelevision

PharmaTelevision Limited ( is based in Oxford, England and is a wholly owned subsidiary of PharmaVentures Ltd, a leading international corporate advisory firm supporting its clients' growth ambitions through licensing, joint ventures and M&A in the healthcare industry ( ). It produces the highly popular PharmaDeals(R) ( range of intelligence products including analysis tools and reports. In 2006, it launched the world's first dedicated online pharmaceutical television channel PharmaTelevision(R) (

PharmaDeals(R) is a registered Trade Mark of PharmaVentures Ltd. For more information on PharmaDeals v4 or to request a demonstration, please contact the PharmaDeals v4 Team: E-mail: Tel: +44(0)1865-332-726

SOURCE PharmaTelevision Ltd
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Reportlinker Adds Downstream Processing in Biopharmaceuticals - Increased Demand for Biologics Drives Improvement in Cost -effective Purification Technologies
2. Biopharma Leaders to Reveal Successful Strategies for China, India at the PharmAsia Summit in San Francisco
3. Helix BioPharma Completes Definitive GLP Toxicology Studies With L-DOS47 and is Making Final Preparations for its Planned Phase I/II Clinical Study IND/CTA Submissions
4. Genesis Biopharma to Present at the Informed Investors Forum Biotech, Healthcare & Pharma Virtual Conference on October 13
5. PDL BioPharma Completes October 1 Special Dividend Payment
6. Genesis Biopharma Announces $700K Private Financing
7. Signal Genetics Announces Partnership with Array BioPharma to Advance a Multiple Myeloma Program Backed by Companion Diagnostics
8. Keryx Biopharmaceuticals to Present at the UBS 2010 Global Life Sciences Conference
9. Helix BioPharma Approved for NYSE Amex Listing
10. PDL BioPharma Provides Clarification Regarding Redemption of Its 2.75% Convertible Subordinated Notes
11. PDL BioPharma Provides Third Quarter 2010 Revenue Guidance of Approximately $86 Million and Update to its Correspondence With Genentech
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... A long-standing partnership ... Professionals (OPBAP) has been formalized with the signing of a Memorandum of Understanding. ... OPBAP leaders Capt. Karl Minter and Capt. Albert Glenn Tuesday, November 24, 2015, ...
(Date:11/25/2015)... ... November 25, 2015 , ... Jessica Richman and Zachary ... in their initial angel funding process. Now, they are paying it forward to ... early stage investments in the microbiome space. In this, they join other ...
(Date:11/24/2015)... 2015 Cepheid (NASDAQ: CPHD ) today ... following conference, and invited investors to participate via webcast. ...      Tuesday, December 1, 2015 at 11.00 a.m. Eastern Time ...      Tuesday, December 1, 2015 at 11.00 a.m. Eastern Time ... New York, NY      Tuesday, December 1, 2015 ...
(Date:11/24/2015)... ... November 24, 2015 , ... Copper ... unless it is bound to proteins, copper is also toxic to cells. With ... Worcester Polytechnic Institute (WPI) will conduct a systematic study of copper in the ...
Breaking Biology Technology:
(Date:11/12/2015)... BOSTON , Nov. 12, 2015  A golden ... for Duchenne muscular dystrophy (DMD) has provided a new ... Boston Children,s Hospital, the Broad Institute of MIT and ... Brazil . Cell, ... some dogs "escape" the disease,s effects. The Boston Children,s ...
(Date:11/10/2015)... , Nov. 10, 2015  In ... on the basis of product, type, application, ... included in this report are consumables, services, ... report are safety biomarkers, efficacy biomarkers, and ... this report are diagnostics development, drug discovery ...
(Date:11/4/2015)... , November 4, 2015 ... new market report published by Transparency Market Research "Home Security ... Trends and Forecast 2015 - 2022", the global home security ... 30.3 bn by 2022. The market is estimated to ... period from 2015 to 2022. Rising security needs among ...
Breaking Biology News(10 mins):